TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms
Schimmer, Roman R. TP53 mutations confer resistance to hypomethylating agents and BCL-2 inhibition in myeloid neoplasms. 2022, University of Zurich, Faculty of Medicine.
Additional indexing
| Item Type: | Dissertation (monographical) |
|---|---|
| Referees: | Boettcher Steffen |
| Communities & Collections: | 04 Faculty of Medicine > University Hospital Zurich > Clinic for Clinical Pharmacology and Toxicology
UZH Dissertations |
| Dewey Decimal Classification: | 610 Medicine & health |
| Language: | English |
| Date: | 2022 |
| Deposited On: | 16 Jan 2023 15:37 |
| Last Modified: | 21 May 2024 20:16 |
| OA Status: | Green |
| Free access at: | Related URL. An embargo period may apply. |
| Related URLs: | https://www.zora.uzh.ch/id/eprint/221976/ https://pubmed.ncbi.nlm.nih.gov/35026842/ https://ashpublications.org/bloodadvances/article/6/11/3201/483517/TP53-mutations-confer-resistance-to |
Permanent URL
https://doi.org/10.5167/uzh-226983
Download
Preview
- Content: Published Version
- Licence:
Schimmer, Roman R